Cover Image
市場調查報告書

白細胞介素13 (IL13) :開發中產品分析

Interleukin 13 (IL13) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364844
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素13 (IL13) :開發中產品分析 Interleukin 13 (IL13) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 56 Pages
簡介

本報告提供以白細胞介素13 (IL13) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

白細胞介素13 (IL13)的概要

治療藥的開發

白細胞介素13 (IL13) :開發中的產品 - 各開發階段

白細胞介素13 (IL13) :開發中的產品 - 各治療範圍

白細胞介素13 (IL13) :開發中的產品 - 各適應症

白細胞介素13 (IL13) :開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

白細胞介素13 (IL13) :企業開發中的產品

白細胞介素13 (IL13) :大學/機關開發中的產品

白細胞介素13 (IL13) :治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

白細胞介素13 (IL13)的治療藥開發企業

  • Celgene Corporation
  • Delenex Therapeutics AG
  • F. Hoffmann-La Roche Ltd.
  • MedImmune, LLC
  • Neovacs SA
  • Novartis AG
  • Sanofi

藥物簡介

白細胞介素13 (IL13) :暫停中的計劃

白細胞介素13 (IL13) :開發中止的產品

白細胞介素13 (IL13) :主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0124TDB

Summary

Global Markets Direct's, 'Interleukin 13 (IL13) - Pipeline Review, H1 2016', provides in depth analysis on Interleukin 13 (IL13) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 13 (IL13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 13 (IL13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 13 (IL13)
  • The report reviews Interleukin 13 (IL13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 13 (IL13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 13 (IL13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 13 (IL13) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 13 (IL13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 13 (IL13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 13 (IL13) Overview
  • Therapeutics Development
    • Interleukin 13 (IL13) - Products under Development by Stage of Development
    • Interleukin 13 (IL13) - Products under Development by Therapy Area
    • Interleukin 13 (IL13) - Products under Development by Indication
  • Interleukin 13 (IL13) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 13 (IL13) - Products under Development by Companies
  • Interleukin 13 (IL13) - Products under Development by Universities/Institutes
  • Interleukin 13 (IL13) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 13 (IL13) - Companies Involved in Therapeutics Development
    • Celgene Corporation
    • Delenex Therapeutics AG
    • F. Hoffmann-La Roche Ltd.
    • MedImmune, LLC
    • Neovacs SA
    • Novartis AG
    • Sanofi
  • Interleukin 13 (IL13) - Drug Profiles
    • (dectrekumab + VAK-694) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dectrekumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lebrikizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-7836 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPC-4046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-156597 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tralokinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 13 (IL13) - Dormant Projects
  • Interleukin 13 (IL13) - Discontinued Products
  • Interleukin 13 (IL13) - Featured News & Press Releases
    • Feb 29, 2016: Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma
    • Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
    • Aug 14, 2014: AstraZeneca advances tralokinumab to Phase III in severe asthma
    • May 12, 2014: AstraZeneca to present respiratory data on tralokinumab at ATS 2014 International Conference
    • Mar 05, 2014: Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma
    • Aug 04, 2011: Roche's Investigational Treatment For Asthma Meets Primary Endpoint In Phase II Study
    • Apr 15, 2008: MedImmune Advances Asthma Program With Start Of A Phase 2 Trial In Europe And Australia And First U.S.-Based Clinical Trial For Antibody Targeting IL-13
    • Mar 18, 2008: MedImmune Advances Clinical Development Of Antibody Targeting Interleukin-9 In Patients With Asthma
    • May 25, 2005: Preclinical Data Support Link Between IL-9 And Airway Hyper-responsiveness Associated With Asthma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Celgene Corporation, H1 2016
  • Pipeline by Delenex Therapeutics AG, H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by MedImmune, LLC, H1 2016
  • Pipeline by Neovacs SA, H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Sanofi, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top